Allergy Therapeutics (AGY) Share Price, News & Analysis

Company Overview

Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut. The company develops allergy vaccines for pollen, house dust mites, and animal fur, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

Key Stats

• Today's Range: 5.03 to 5.30
• 50-Day Range: 4.05 to 5.60
• 52-Week Range: 1.65 to 6.30
• Volume: 215,093 shs
• Average Volume: 696,673 shs
• Market Capitalization: £248.04 million
• P/E Ratio: N/A
• Dividend Yield: 8.33%
• Price Target: N/A
• Consensus Rating: N/A

AGY Stock Analysis - Frequently Asked Questions

How have AGY shares performed this year?

Allergy Therapeutics' stock was trading at GBX 2.50 at the beginning of 2024. Since then, AGY shares have increased by 101.2% and is now trading at GBX 5.03.
View the best growth stocks for 2024 here.

How were Allergy Therapeutics' earnings last quarter?

Allergy Therapeutics plc (LON:AGY) posted its quarterly earnings data on Wednesday, March, 4th. The company reported $2.40 earnings per share (EPS) for the quarter. Allergy Therapeutics had a negative net margin of 94.29% and a negative trailing twelve-month return on equity of 155.90%.

How do I buy shares of Allergy Therapeutics?

Shares of AGY stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Allergy Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Allergy Therapeutics investors own include (RLYP) (RLYP), Royalty Pharma (RPRX), genedrive (GDR), Intel (INTC), IQE (IQE), AstraZeneca (AZN) and Babcock International Group (BAB).

Company Calendar

• Last Earnings: 3/04/2020
• Today: 11/21/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: LON:AGY
• CUSIP: N/A
• CIK: N/A
• Web: www.allergytherapeutics.com
• Phone: +44-1903-844700
• Fax: N/A
• Employees: 612
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: -30.7
• Net Income: £-50,220,000.00
• Net Margins: -94.29%
• Pretax Margin: N/A
• Return on Equity: -155.90%
• Return on Assets: -34.76%

Debt

• Debt-to-Equity Ratio: 37.22
• Current Ratio: 1.40
• Quick Ratio: 1.48

Sales & Book Value

• Annual Sales: £53.26 million
• Price / Sales: 4.57
• Cash Flow: GBX 1.39 per share
• Price / Cash Flow: 3.66
• Book Value: GBX 1 per share
• Price / Book: 5.10

Miscellaneous

• Outstanding Shares: 4,770,000,000
• Free Float: N/A
• Market Cap: £243.27 million
• Optionable: Not Optionable
• Beta: 1.40